Lucid Diagnostics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 70
- Market Cap
- -
- Introduction
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
Novel Screening Technologies Enter Clinical Trial to Detect Silent Esophageal Precancer
University Hospitals and Case Western Reserve University launch an $8 million NIH-funded clinical trial to evaluate EsoCheck and EsoGuard technologies for detecting Barrett's Esophagus in non-GERD patients.
Lucid Diagnostics Expands EsoGuard Access Through Concierge Medicine and Secures First Commercial Insurance Coverage
Lucid Diagnostics has partnered with LEAA Health to offer its EsoGuard Esophageal DNA Test to concierge medicine patients on a cash-pay basis, targeting the growing $10.9 billion concierge medicine market projected by 2032.
EsoGuard Esophageal DNA Test Demonstrates High Clinical Utility in Detecting Barrett's Esophagus
A new study demonstrates the clinical utility of Lucid Diagnostics' EsoGuard test for detecting Barrett's Esophagus.